Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer's disease pathophysiology in cognitively unimpaired older adults.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
11
07
2022
accepted:
01
11
2022
revised:
07
10
2022
pubmed:
9
12
2022
medline:
15
3
2023
entrez:
8
12
2022
Statut:
ppublish
Résumé
Attention-deficit/hyperactivity disorder (ADHD) persists in older age and is postulated as a risk factor for cognitive impairment and Alzheimer's Disease (AD). However, these findings rely primarily on electronic health records and can present biased estimates of disease prevalence. An obstacle to investigating age-related cognitive decline in ADHD is the absence of large-scale studies following patients with ADHD into older age. Alternatively, this study aimed to determine whether genetic liability for ADHD, as measured by a well-validated ADHD polygenic risk score (ADHD-PRS), is associated with cognitive decline and the development of AD pathophysiology in cognitively unimpaired (CU) older adults. We calculated a weighted ADHD-PRS in 212 CU individuals without a clinical diagnosis of ADHD (55-90 years). These individuals had baseline amyloid-β (Aβ) positron emission tomography, longitudinal cerebrospinal fluid (CSF) phosphorylated tau at threonine 181 (p-tau
Identifiants
pubmed: 36476732
doi: 10.1038/s41380-022-01867-2
pii: 10.1038/s41380-022-01867-2
doi:
Substances chimiques
Amyloid beta-Peptides
0
tau Proteins
0
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1248-1255Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder. Neurosci Biobehav Rev. 2021 https://www.sciencedirect.com/science/article/pii/S014976342100049X
Caye A, Spadini AV, Karam RG, Grevet EH, Rovaris DL, Bau CHD, et al. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry. 2016;25:1151–9.
doi: 10.1007/s00787-016-0831-8
pubmed: 27021056
Kooij JJS, Michielsen M, Kruithof H, Bijlenga D. ADHD in old age: a review of the literature and proposal for assessment and treatment. Expert Rev Neurother. 2016;16:1371–81.
doi: 10.1080/14737175.2016.1204914
pubmed: 27334252
Dobrosavljevic M, Solares C, Cortese S, Andershed H, Larsson H. Prevalence of attention-deficit/hyperactivity disorder in older adults: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2020;118:282–9. https://doi.org/10.1016/j.neubiorev.2020.07.042 .
doi: 10.1016/j.neubiorev.2020.07.042
pubmed: 32798966
Callahan BL, Bierstone D, Stuss DT, Black SE. Adult ADHD: Risk factor for dementia or phenotypic mimic? Front Aging Neurosci. 2017;9:1–15.
doi: 10.3389/fnagi.2017.00260
Du Rietz E, Brikell I, Butwicka A, Leone M, Chang Z, Cortese S, et al. Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study. Lancet Psychiatry. 2021;8:774–83. Available from: https://doi.org/10.1016/S2215-0366(21)00171-1
Zhang L, Du Rietz E, Kuja-Halkola R, Dobrosavljevic M, Johnell K, Pedersen NL, et al. Attention-deficit/hyperactivity disorder and Alzheimer’s disease and any dementia: A multi-generation cohort study in Sweden. Alzheimer’s Dement. 2020;2021:1–9.
Dobrosavljevic M, Zhang L, Garcia-Argibay M, Du Rietz E, Andershed H, Chang Z, et al. Attention-deficit/hyperactivity disorder as a risk factor for dementia and mild cognitive impairment: A population-based register study. Eur Psychiatry. 2022;65:e3. https://www.cambridge.org/core/article/attentiondeficithyperactivity-disorder-as-a-risk-factor-for-dementia-and-mild-cognitive-impairment-a-populationbased-register-study/E289DAD7BE1BFB781389CF369EF7ECB3
doi: 10.1192/j.eurpsy.2021.2261
Becker S, Sharma MJ, Callahan BL. ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence. Front Aging Neurosci. 2022;13.
Ronald A, de Bode N, Polderman TJC. Systematic review: how the attention-deficit/hyperactivity disorder polygenic risk score adds to our understanding of ADHD and associated traits. J Am Acad Child Adolesc Psychiatry. 2021;60:1234–77.
Thapar A. Discoveries on the genetics of ADHD in the 21st Century: New findings and their implications. Am J Psychiatry. 2018;175:943–50.
doi: 10.1176/appi.ajp.2018.18040383
pubmed: 30111187
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201–9.
doi: 10.1212/WNL.0b013e3181cb3e25
pubmed: 20042704
pmcid: 2809036
Zettergren A, Lord J, Ashton NJ, Benedet AL, Karikari TK, Lantero Rodriguez J, et al. Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Res Ther. 2021;13:17. https://doi.org/10.1186/s13195-020-00754-8 .
doi: 10.1186/s13195-020-00754-8
pubmed: 33419453
pmcid: 7792087
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51:63–75.
doi: 10.1038/s41588-018-0269-7
pubmed: 30478444
Euesden J, Lewis CM, O’Reilly PF. PRSice: Polygenic Risk Score software. Bioinformatics. 2015;31:1466–8.
doi: 10.1093/bioinformatics/btu848
pubmed: 25550326
Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.
doi: 10.1186/s13742-015-0047-8
pubmed: 25722852
pmcid: 4342193
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline. JAMA Neurol. 2014;71:961–70.
doi: 10.1001/jamaneurol.2014.803
pubmed: 24886908
pmcid: 4439182
Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517–27.
doi: 10.1007/s11682-012-9176-1
pubmed: 22644789
pmcid: 3684181
Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6:502–16.
doi: 10.1007/s11682-012-9186-z
pubmed: 22782295
pmcid: 3806057
Jack CRJ, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–91.
doi: 10.1002/jmri.21049
pubmed: 18302232
pmcid: 2544629
Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578–86.
doi: 10.1002/ana.23650
pubmed: 23109153
pmcid: 3786871
Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470–81.
doi: 10.1016/j.jalz.2018.01.010
pubmed: 29499171
pmcid: 6119541
Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MS, et al. VoxelStats: A MATLAB Package for multi-modal voxel-wise brain image analysis. 10, Front Neuroinformatics. 2016. Available from: https://www.frontiersin.org/article/10.3389/fninf.2016.00020
Selya A, Rose J, Dierker L, Hedeker D, Mermelstein R. A Practical Guide to Calculating Cohen’s f2, a Measure of Local Effect Size, from PROC MIXED. Vol. 3, Front Psychol. 2012. Available from: https://www.frontiersin.org/article/10.3389/fpsyg.2012.00111
Keller MC. Gene × environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. Biol Psychiatry. 2014;75:18–24.
doi: 10.1016/j.biopsych.2013.09.006
pubmed: 24135711
Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Prim. 2021;7:33 https://doi.org/10.1038/s41572-021-00269-y . Available from
doi: 10.1038/s41572-021-00269-y
pubmed: 33986301
Ferrari-Souza JP, Brum WS, Hauschild LA, Da Ros LU, Lukasewicz Ferreira PC, Bellaver B, et al. Vascular risk burden is a key player in the early progression of Alzheimer’s disease. medRxiv. 2021.12.18.21267994. http://medrxiv.org/content/early/2021/12/19/2021.12.18.21267994.abstract
Mendonca F, Sudo FK, Santiago-Bravo G, Oliveira N, Assuncao N, Rodrigues F, et al. Mild cognitive impairment or attention-deficit/hyperactivity disorder in older adults? A cross sectional study. Front Psychiatry. 2021;12:12–7.
doi: 10.3389/fpsyt.2021.737357
Ossenkoppele R, Binette AP, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline? medRxiv. 2022;2022.05.23.22275241. http://medrxiv.org/content/early/2022/05/25/2022.05.23.22275241.abstract
Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner M, Aisen PS. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA - J Am Med Assoc. 2017;317:2305–16.
doi: 10.1001/jama.2017.6669
Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 2022;79:975–85. https://doi.org/10.1001/jamaneurol.2022.2379 .
Jack CRJ, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of Amyloid, Tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321:2316–25.
doi: 10.1001/jama.2019.7437
pubmed: 31211344
pmcid: 6582267
Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of Amyloid and Tau with cognition in preclinical Alzheimer disease: A Longitudinal Study. JAMA Neurol. 2019;76:915–24. https://doi.org/10.1001/jamaneurol.2019.1424 .
doi: 10.1001/jamaneurol.2019.1424
pubmed: 31157827
pmcid: 6547132
Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019;179:312–39. https://doi.org/10.1016/j.cell.2019.09.001 .
doi: 10.1016/j.cell.2019.09.001
pubmed: 31564456
pmcid: 6778042
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence estimates of amyloid abnormality across the alzheimer disease clinical spectrum. JAMA Neurol. 2022 https://doi.org/10.1001/jamaneurol.2021.5216
La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, et al. Associations between [(18)F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology. 2018;90:e282–90.
doi: 10.1212/WNL.0000000000004860
pubmed: 29282337
pmcid: 5798657
Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67–77. https://pubmed.ncbi.nlm.nih.gov/20139996
doi: 10.1038/nrneurol.2009.215
pubmed: 20139996
pmcid: 2938772
Moreno-Alcázar A, Ramos-Quiroga JA, Radua J, Salavert J, Palomar G, Bosch R, et al. Brain abnormalities in adults with Attention Deficit Hyperactivity Disorder revealed by voxel-based morphometry. Psychiatry Res Neuroimaging. 2016;254:41–7. https://www.sciencedirect.com/science/article/pii/S0925492715301815
doi: 10.1016/j.pscychresns.2016.06.002
pubmed: 27318593
Klein M, Souza-Duran FL, Menezes AKPM, Alves TM, Busatto G, Louzã MR. Gray matter volume in elderly adults With ADHD: Associations of symptoms and comorbidities with brain structures. J Atten Disord. 2021;25:829–38.
doi: 10.1177/1087054719855683
pubmed: 31262214
Fuermaier ABM, Tucha L, Koerts J, Aschenbrenner S, Weisbrod M, Lange KW, et al. Cognitive complaints of adults with attention deficit hyperactivity disorder. Clin Neuropsychol. 2014;28:1104–22.
doi: 10.1080/13854046.2014.964325
pubmed: 25270667